Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Diarrhea 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Filgrastim 13Carboplatin 10Cyclophosphamide 9pembrolizumab 8Radiosurgery 8Ifosfamide 8Magnetic Resonance Spectroscopy 7Etoposide 7Biopsy 7Specimen Handling 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Paclitaxel 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cisplatin 5pazopanib 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Nivolumab 4Mesna 4Melphalan 4Docetaxel 4Busulfan 4Blood Specimen Collection 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Octreotide × Genitourinary × Clear all
NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Alliance for Clinical Trials in Oncology

Phase 3 Completed
130 enrolled
GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡